cash flow generated from operations and good working capital management. (b) Total Liabilities Total liability as of September 30, 2019 was 168.73mb, increasing by 61.42mb or 57.2% , m ainly due to the
operation and increase in the Company’s financial liquidity, used as working capital and to repay debt which would help reduce the interest burden of the Company. On the date that the Board of Directors
Commission governing the maintenance of financial status of a licensed securities company; (2) shareholders’ equity as shown in the latest financial statement that has been audited by an auditor approved by
) shareholders’ equity as shown in the latest financial statement that has been audited by an auditor approved by the Office shall be positive. In case where the securities company increase its paid-up capital
governing the maintenance of financial status of a licensed derivatives broker; (2) shareholders’ equity as shown in the latest financial statement that has been audited by an auditor approved by the Office
of the Securities and Exchange Commission governing the maintenance of financial status of a licensed derivatives broker; (2) shareholders’ equity as shown in the latest financial statement that has
Limited for the three months period ended March 31, 2019. And The Audited financial statement of BS Myco Biotech Company Limited for year ended December 31,2018. The calculation of transaction size (1) Book
credit agreement for working capital purpose and subsidiary had a plant shut down due to the breakdown of important equipment. Selling Expenses The Company recorded selling expense of Baht 34 million